Skip to main content
Top
Published in: Journal of Anesthesia 2/2015

01-04-2015 | Original Article

Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients

Authors: Takayuki Kunisawa, Akio Yamagishi, Manabu Suno, Susumu Nakade, Ryunosuke Higashi, Atsushi Kurosawa, Ami Sugawara, Kazuo Matsubara, Hiroshi Iwasaki

Published in: Journal of Anesthesia | Issue 2/2015

Login to get access

Abstract

Purpose

We previously determined the pharmacokinetic (PK) parameters of landiolol in healthy male volunteers. In this study, we evaluated the usefulness of target-controlled infusion (TCI) of landiolol hydrochloride and determined PK parameters of landiolol in gynecologic patients.

Methods

Nine patients who were scheduled to undergo gynecologic surgery were enrolled. After inducing anesthesia, landiolol hydrochloride was administered at the target plasma concentrations of 500 and 1,000 ng/mL for each 30 min. A total of 126 data points of plasma concentration were collected from the patients and used for the population PK analysis. Furthermore, a population PK model was developed using the nonlinear mixed-effect modeling software.

Results

The patients had markedly decreased heart rates (HRs) at 2 min after the initiation of landiolol hydrochloride administration; however, their blood pressures did not markedly change from the baseline value. The concentration time course of landiolol was best described by a 2-compartment model with lag time. The estimate of PK parameters were total body clearance (CL) 34.0 mL/min/kg, distribution volume of the central compartment (V 1) 74.9 mL/kg, inter-compartmental clearance (Q) 70.9 mL/min/kg, distribution volume of the peripheral compartment (V 2) 38.9 mL/kg, and lag time (ALAG) 0.634 min. The predictive performance of this model was better than that of the previous model.

Conclusion

TCI of landiolol hydrochloride is useful for controlling HR, and the PK parameters of landiolol in gynecologic patients were similar to those in healthy male volunteers and best described by a 2-compartment model with lag time.
Literature
1.
go back to reference Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers. Rinsho Iyaku. 2000;16:1531–56. Nakashima M, Kanamaru M. Phase I study of ONO-1101, a new ultra short acting β1-blocking agent in healthy volunteers. Rinsho Iyaku. 2000;16:1531–56.
2.
go back to reference Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sasaki K, Hachiya K, Ichioka Y, Kanamaru M. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull. 1992;40:1462–9.CrossRefPubMed Iguchi S, Iwamura H, Nishizaki M, Hayashi A, Senokuchi K, Kobayashi K, Sasaki K, Hachiya K, Ichioka Y, Kanamaru M. Development of a highly cardioselective ultra short-acting β-blocker, ONO-1101. Chem Pharm Bull. 1992;40:1462–9.CrossRefPubMed
3.
go back to reference Yoshida Y, Terajima K, Sato C, Akada S, Miyagi Y, Hongo T, Takeda S, Tanaka K, Sakamoto A. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22:64–9.CrossRefPubMed Yoshida Y, Terajima K, Sato C, Akada S, Miyagi Y, Hongo T, Takeda S, Tanaka K, Sakamoto A. Clinical role and efficacy of landiolol in the intensive care unit. J Anesth. 2008;22:64–9.CrossRefPubMed
4.
go back to reference Honda N, Nakade S, Kasai H, Hashimoto Y, Ohno T, Kitagawa J, Yamauchi A, Hasegawa C, Kikawa S, Kunisawa T, Tanigawara Y, Miyata Y. Population pharmacokinetics of landiolol hydrochloride in healthy subjects. Drug Metab Pharmacokinet. 2008;23:447–55.CrossRefPubMed Honda N, Nakade S, Kasai H, Hashimoto Y, Ohno T, Kitagawa J, Yamauchi A, Hasegawa C, Kikawa S, Kunisawa T, Tanigawara Y, Miyata Y. Population pharmacokinetics of landiolol hydrochloride in healthy subjects. Drug Metab Pharmacokinet. 2008;23:447–55.CrossRefPubMed
5.
go back to reference Shafer SL, Varvel JR, Aziz N, Scott JC. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology. 1990;73:1091–102.CrossRefPubMed Shafer SL, Varvel JR, Aziz N, Scott JC. Pharmacokinetics of fentanyl administered by computer-controlled infusion pump. Anesthesiology. 1990;73:1091–102.CrossRefPubMed
6.
go back to reference Suno M, Kunisawa T, Yamagishi A, Ono T, Yamamoto J, Yamada T, Tasaki Y, Shimizu K, Iwasaki H, Matsubara K. Detection of landiolol using high-performance liquid chromatography/fluorescence: a blood esterase-sensitive ultra-short-acting beta(1)-receptor antagonist. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1705–8.CrossRefPubMed Suno M, Kunisawa T, Yamagishi A, Ono T, Yamamoto J, Yamada T, Tasaki Y, Shimizu K, Iwasaki H, Matsubara K. Detection of landiolol using high-performance liquid chromatography/fluorescence: a blood esterase-sensitive ultra-short-acting beta(1)-receptor antagonist. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877:1705–8.CrossRefPubMed
7.
go back to reference Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78:821–8.CrossRefPubMed Dyck JB, Maze M, Haack C, Azarnoff DL, Vuorilehto L, Shafer SL. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers. Anesthesiology. 1993;78:821–8.CrossRefPubMed
8.
go back to reference Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187–97.CrossRefPubMed Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24:2187–97.CrossRefPubMed
9.
go back to reference Sepulveda P, Cortinez LI, Saez C, Penna A, Solari S, Guerra I, Absalom AR. Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children. Br J Anaesth. 2011;107:593–600.CrossRefPubMed Sepulveda P, Cortinez LI, Saez C, Penna A, Solari S, Guerra I, Absalom AR. Performance evaluation of paediatric propofol pharmacokinetic models in healthy young children. Br J Anaesth. 2011;107:593–600.CrossRefPubMed
10.
go back to reference Glass PS, Shafer S, Reves JG. Intravenous drug delivery systems. In: Miller RD, editor. Miller’s anesthesia. 6th ed. Philadelphia: Churchill Livingstone; 2005. p. 439–80. Glass PS, Shafer S, Reves JG. Intravenous drug delivery systems. In: Miller RD, editor. Miller’s anesthesia. 6th ed. Philadelphia: Churchill Livingstone; 2005. p. 439–80.
11.
go back to reference Passot S, Servin F, Allary R, Pascal J, Prades JM, Auboyer C, Molliex S. Target-controlled versus manually-controlled infusion of propofol for direct laryngoscopy and bronchoscopy. Anesth Analg. 2002;94:1212–6 (table of contents).CrossRefPubMed Passot S, Servin F, Allary R, Pascal J, Prades JM, Auboyer C, Molliex S. Target-controlled versus manually-controlled infusion of propofol for direct laryngoscopy and bronchoscopy. Anesth Analg. 2002;94:1212–6 (table of contents).CrossRefPubMed
12.
go back to reference De Castro V, Godet G, Mencia G, Raux M, Coriat P. Target-controlled infusion for remifentanil in vascular patients improves hemodynamics and decreases remifentanil requirement. Anesth Analg. 2003;96:33–8 (table of contents).PubMed De Castro V, Godet G, Mencia G, Raux M, Coriat P. Target-controlled infusion for remifentanil in vascular patients improves hemodynamics and decreases remifentanil requirement. Anesth Analg. 2003;96:33–8 (table of contents).PubMed
13.
go back to reference Vermeyen KM, Hoffmann VL, Saldien V. Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. Br J Anaesth. 2003;90:183–8.CrossRefPubMed Vermeyen KM, Hoffmann VL, Saldien V. Target controlled infusion of rocuronium: analysis of effect data to select a pharmacokinetic model. Br J Anaesth. 2003;90:183–8.CrossRefPubMed
14.
go back to reference Lehtonen LA, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43:187–203.CrossRefPubMed Lehtonen LA, Antila S, Pentikainen PJ. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43:187–203.CrossRefPubMed
15.
go back to reference Takahata T, Yasui-Furukori N, Sakamoto J, Suto K, Suto T, Tateishi T, Munakata A. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. Drugs R D. 2005;6:385–94.CrossRefPubMed Takahata T, Yasui-Furukori N, Sakamoto J, Suto K, Suto T, Tateishi T, Munakata A. Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of landiolol hydrochloride, an ultra-short-acting beta1-blocker. Drugs R D. 2005;6:385–94.CrossRefPubMed
16.
go back to reference de Bruijn NP, Reves JG, Croughwell N, Clements F, Drissel DA. Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy. Anesthesiology. 1987;66:323–6.CrossRefPubMed de Bruijn NP, Reves JG, Croughwell N, Clements F, Drissel DA. Pharmacokinetics of esmolol in anesthetized patients receiving chronic beta blocker therapy. Anesthesiology. 1987;66:323–6.CrossRefPubMed
17.
go back to reference Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31–41.CrossRefPubMed
Metadata
Title
Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients
Authors
Takayuki Kunisawa
Akio Yamagishi
Manabu Suno
Susumu Nakade
Ryunosuke Higashi
Atsushi Kurosawa
Ami Sugawara
Kazuo Matsubara
Hiroshi Iwasaki
Publication date
01-04-2015
Publisher
Springer Japan
Published in
Journal of Anesthesia / Issue 2/2015
Print ISSN: 0913-8668
Electronic ISSN: 1438-8359
DOI
https://doi.org/10.1007/s00540-014-1908-5

Other articles of this Issue 2/2015

Journal of Anesthesia 2/2015 Go to the issue